Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI tool aims to cut allergy misdiagnosis in primary care

NCT ID NCT07631039

Diagnosis Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether AI-powered decision trees can help general practitioners better diagnose and manage allergies. About 600 patients with suspected allergies will be enrolled, and doctors will use an app that suggests next steps based on symptoms. The goal is to see if this tool reduces incorrect diagnoses and unnecessary referrals to specialists, improving care for common allergic conditions like asthma, food allergy, and hives.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI-automated decision trees on an application
What this could lead to
If successful, this could provide GPs with a simple, effective tool to better diagnose and manage allergies, reducing misdiagnosis and unnecessary specialist visits.
What could go wrong
This is an early-stage validation study with no phase, so results may not confirm effectiveness. The tool's success depends on ease of use and integration into daily practice, which may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

1 year and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with suspected asthma, anaphylaxis, drug allergy, food allergy, rhinitis and urticaria. * Patients aged 1 year or older at inclusion, registered with a health insurance plan. * Patient or legal representative of the minor patient who agrees to participate in the research. Exclusion Criteria: * Adults placed under guardianship or curatorship. * Patients already followed by an allergist and/or a specialist doctor for their allergies. * Patients who participate in a clinical research study relating to an antiallergic medication, immunosuppressant, immunomodulator in the year preceding their consultation visit with the GP.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Allergy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

allergic disease anaphylaxis asthma disease drug allergy food allergy rhinitis urticaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Allergy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Département Universitaire de Médecine Générale MSPU CHU Montpellier

    Saint-Georges-dOrques, Occitanie, 34680, France

  • MSP Calypso

    Roujan, Occitanie, 34320, France

  • MSP Pézenas-Tourbes

    Tourbes, Occitanie, 34120, France

  • MSP Universitaire Avicenne

    Cabestany, Occitanie, 66330, France

  • Msp Beau Art

    Perpignan, Occitanie, 66000, France

  • Msp Charles Gide

    Nîmes, Occitanie, 30000, France

  • Msp Espace Sante Servian

    Béziers, Occitanie, 34500, France

  • Msp Montpellier -Cevenne

    Montpellier, Occitanie, 34080, France

  • Msp Narbo Ouest

    Narbonne, Occitanie, 11100, France

  • Msp Sud Minevoir

    Saint-Marcel-sur-Aude, Occitanie, 11120, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.